ctDNA is not a simple positive/negative binary test. Like PSA in prostate cancer, the quantitative level of ctDNA correlates with patient outcomes. Higher levels indicate a worse prognosis and a faster time to relapse, allowing for more nuanced risk stratification beyond a simple presence or absence of the biomarker.

The prognostic value of a positive ctDNA test in urothelial cancer intensifies throughout the treatment journey. Failure to clear ctDNA after neoadjuvant therapy and then surgery is associated with a dramatically increasing hazard ratio for death, signaling profound treatment failure.

Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.

Circulating tumor DNA (ctDNA) is a powerful biomarker for identifying high-risk bladder cancer patients. However, its imperfection presents a new clinical dilemma: with a ~12% relapse rate even in ctDNA-negative patients, clinicians must decide whether to withhold adjuvant therapy and accept that risk, or overtreat the 88% who are likely cured.

In adjuvant bladder cancer trials, ctDNA status is both prognostic and predictive. Patients with positive ctDNA after surgery are at high risk of relapse but benefit from immune checkpoint inhibitors. Conversely, ctDNA-negative patients have a lower risk and derive no benefit, making ctDNA a critical tool to avoid unnecessary, toxic therapy.

In muscle-invasive bladder cancer, patients whose cell-free DNA remains positive after surgery almost uniformly experience disease relapse. This makes ctDNA a powerful prognostic tool, akin to PSA in prostate cancer, for identifying patients at the highest risk.

Beyond a simple positive/negative result, the quantitative level of ctDNA is highly prognostic in bladder cancer. Similar to PSA in prostate cancer, higher ctDNA levels correlate with a significantly worse prognosis, offering a more nuanced risk assessment tool than a binary test.

A positive circulating tumor DNA (ctDNA) test in a patient with a known bladder tumor can be misinterpreted as metastatic disease. However, the local tumor itself sheds DNA. Resecting this tumor can clear the ctDNA signal, a critical nuance to prevent misdiagnosis and premature, aggressive systemic therapy.

A positive ctDNA result post-surgery in an immunotherapy-naive patient warrants starting treatment. Conversely, if a patient received neoadjuvant immunotherapy and remains ctDNA positive after surgery, it signals resistance, making continuation of the same therapy illogical and creating a clinical paradox.